Next Step in Chronic Kidney Disease Therapy
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers are the basis of renoprotection therapy in chronic kidney disease. Parallel to decrease of glomerular filtration rate, there is an increase in the activity of the sympathetic nervous system, and the number of functioning nephrons reduces, which requires a change of treatment regimen. Reducing the risk of cardiovascular events on the background of increased hypertension probably dictates the need for a priority administration of sympatholytics, calcium channel blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers withdrawal. ARAMONEL formula: ARAMONEL — AR(B)A(CEI)MO(xonidine)NE(bivolol)L(ercandipine) is changed to MNELD — M(oxonidine)NE(bivolol)L(ercandipine)D(iuretic) that is used by us in recent years. Combined use of torsemide and xipamide is allowed. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers withdrawal requires evidence, which may be obtained in STOP-ACEi trial..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Počki - 6(2016), 2.16, Seite 10-13 |
| Sprache: |
Englisch ; Ukrainisch |
|---|
| Beteiligte Personen: |
D.D. Ivanov [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| doi: |
10.22141/2307-1257.2.16.2016.72205 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ018225829 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ018225829 | ||
| 003 | DE-627 | ||
| 005 | 20230310095059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.22141/2307-1257.2.16.2016.72205 |2 doi | |
| 035 | |a (DE-627)DOAJ018225829 | ||
| 035 | |a (DE-599)DOAJ0644a97c883f4c0e8409cb7ea7f48c98 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a ukr | ||
| 050 | 0 | |a RC870-923 | |
| 100 | 0 | |a D.D. Ivanov |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Next Step in Chronic Kidney Disease Therapy |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers are the basis of renoprotection therapy in chronic kidney disease. Parallel to decrease of glomerular filtration rate, there is an increase in the activity of the sympathetic nervous system, and the number of functioning nephrons reduces, which requires a change of treatment regimen. Reducing the risk of cardiovascular events on the background of increased hypertension probably dictates the need for a priority administration of sympatholytics, calcium channel blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers withdrawal. ARAMONEL formula: ARAMONEL — AR(B)A(CEI)MO(xonidine)NE(bivolol)L(ercandipine) is changed to MNELD — M(oxonidine)NE(bivolol)L(ercandipine)D(iuretic) that is used by us in recent years. Combined use of torsemide and xipamide is allowed. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers withdrawal requires evidence, which may be obtained in STOP-ACEi trial. | ||
| 650 | 4 | |a angiotensin-converting enzyme inhibitor | |
| 650 | 4 | |a angiotensin receptor blockers | |
| 650 | 4 | |a calcium channel blockers | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a estimated glomerular filtration rate | |
| 653 | 0 | |a Diseases of the genitourinary system. Urology | |
| 773 | 0 | 8 | |i In |t Počki |d Zaslavsky O.Yu., 2017 |g 6(2016), 2.16, Seite 10-13 |w (DE-627)DOAJ000141941 |x 23071265 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2016 |g number:2.16 |g pages:10-13 |
| 856 | 4 | 0 | |u https://doi.org/10.22141/2307-1257.2.16.2016.72205 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/0644a97c883f4c0e8409cb7ea7f48c98 |z kostenfrei |
| 856 | 4 | 0 | |u http://kidneys.zaslavsky.com.ua/article/view/72205 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2307-1257 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2307-1265 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2016 |e 2.16 |h 10-13 | ||